These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12186378)

  • 41. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):109-14. PubMed ID: 11850214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
    Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
    Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
    Zilembo N; Noberasco C; Bajetta E; Martinetti A; Mariani L; Orefice S; Buzzoni R; Di Bartolomeo M; Di Leo A; Laffranchi A
    Br J Cancer; 1995 Oct; 72(4):1007-12. PubMed ID: 7547212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
    Chen D; Hackl W; Ortmann O; Treeck O
    Anticancer Drugs; 2004 Jan; 15(1):55-61. PubMed ID: 15090744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The NEOLETEXE trial: a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors.
    Bahrami N; Sauer T; Engebretsen S; Aljabri B; Bemanian V; Lindstrøm J; Lüders T; Kristensen V; Lorentzen A; Loeng M; Ødegård HP; Kvaløy JØ; Vestøl IB; Geisler SB; Gravdehaug B; Gundersen JM; Geisler J
    Future Oncol; 2019 Nov; 15(32):3675-3682. PubMed ID: 31513453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aromatase inhibitors for breast cancer: lessons from the laboratory.
    Johnston SR; Dowsett M
    Nat Rev Cancer; 2003 Nov; 3(11):821-31. PubMed ID: 14668813
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Wang J; Xu B; Wang W; Zhai X; Chen X
    Breast Cancer Res Treat; 2018 Oct; 171(3):535-544. PubMed ID: 29974356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exemestane experience in breast cancer treatment.
    Lønning PE; Paridaens R; Thürlimann B; Piscitelli G; di Salle E
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):151-5. PubMed ID: 9365185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
    Varela CL; Amaral C; Tavares da Silva E; Lopes A; Correia-da-Silva G; Carvalho RA; Costa SC; Roleira FM; Teixeira N
    Eur J Med Chem; 2014 Nov; 87():336-45. PubMed ID: 25277066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Irreversible aromatase inactivation: treatment for breast cancer.
    Johnston SR
    Hosp Med; 2000 Sep; 61(9):650-5. PubMed ID: 11048608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
    Buzdar AU
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):468S-72S. PubMed ID: 12538502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiaromatase agents: evolving role in adjuvant therapy.
    Jones SE
    Clin Breast Cancer; 2002 Apr; 3(1):33-42. PubMed ID: 12020394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New aromatase inhibitors in the treatment of advanced breast cancer.
    Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
    Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
    Telford C; Jones N; Livings C; Batson S
    Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Aromatase inhibitors: pharmacological aspects].
    de Crémoux P
    Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.
    Njar VC; Brodie AM
    Drugs; 1999 Aug; 58(2):233-55. PubMed ID: 10473018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.